[{"id":"66643133-9eb7-4c8b-a339-12d869e2e3a8","acronym":"","url":"https://clinicaltrials.gov/study/NCT04097756","created_at":"2021-01-18T20:03:00.413Z","updated_at":"2024-07-02T16:35:49.231Z","phase":"Phase 1","brief_title":"A Phase I Study of LX-039 Tablets","source_id_and_acronym":"NCT04097756","lead_sponsor":"Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LX-039"],"overall_status":"Completed","enrollment":" Enrollment 44","initiation":"Initiation: 01/07/2020","start_date":" 01/07/2020","primary_txt":" Primary completion: 08/08/2022","primary_completion_date":" 08/08/2022","study_txt":" Completion: 02/07/2023","study_completion_date":" 02/07/2023","last_update_posted":"2023-05-01"}]